Literature DB >> 7671161

Acute effects of bisphosphonates on new and traditional markers of bone resorption.

M Pedrazzoni1, F S Alfano, C Gatti, M Fantuzzi, G Girasole, C Campanini, G Basini, M Passeri.   

Abstract

Bisphosphonates are known to be potent inhibitors of osteoclast activity and their only clinically relevant effect in the short-term is the selective inhibition of bone resorption. The purpose of this study was to compare the response to the intravenous administration of two bisphosphonates, clodronate and alendronate, of several biochemical markers of bone resorption, including tartrate-resistant acid phosphatase (TRAP) and cross-linked carboxyterminal telopeptide of collagen I (ICTP) in serum and hydroxyproline (OHP), free pyridinium cross-links (Pyr), and cross-linked N-telopeptides of collagen I (NTx) in urine. The study was carried out on 11 osteoporotic and 12 Pagetic subjects of both sexes, treated with clodronate (600 mg/day for 2 days) or alendronate (5 mg/day for 2 days), and monitored for 28 days after bisphosphonate administration. All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%. In the osteoporotic group, the urinary markers began to increase again at 30 days, though still remaining well below the basal level, whereas in the pagetic group, the excretion of all markers remained depressed until the end of the observation period. The reduction of NTx was significantly greater than that of Pyr and OHP in pagetic patients (P < 0.05) and tended to be greater than that of Pyr in osteoporotic patients (p = 0.07).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671161     DOI: 10.1007/bf00298992

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  34 in total

1.  Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.

Authors:  D P O'Doherty; D R Bickerstaff; E V McCloskey; N A Hamdy; M N Beneton; S Harris; M Mian; J A Kanis
Journal:  J Bone Miner Res       Date:  1990-05       Impact factor: 6.741

2.  Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women.

Authors:  L Moro; C Modricky; L Rovis; B de Bernard
Journal:  Bone Miner       Date:  1988-01

3.  Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.

Authors:  M J Marshall; I Holt; M W Davie
Journal:  Calcif Tissue Int       Date:  1993-01       Impact factor: 4.333

Review 4.  Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis.

Authors:  P D Delmas
Journal:  Am J Med       Date:  1993-11-30       Impact factor: 4.965

5.  Treatment of Paget's disease of bone with single dose intravenous pamidronate.

Authors:  R A Watts; S J Skingle; M M Bhambhani; G Pountain; A J Crisp
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

6.  Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone.

Authors:  M Pedrazzoni; E Palummeri; G Ciotti; L Davoli; G Pioli; G Girasole; M Passeri
Journal:  Bone Miner       Date:  1989-11

7.  Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?

Authors:  N A Hamdy; S E Papapoulos; A Colwell; R Eastell; R G Russell
Journal:  Bone Miner       Date:  1993-07

8.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.

Authors:  P D Delmas; A Schlemmer; E Gineyts; B Riis; C Christiansen
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

Review 9.  Biochemical markers of bone turnover. II: Diagnosis, prophylaxis, and treatment of osteoporosis.

Authors:  B J Riis
Journal:  Am J Med       Date:  1993-11-30       Impact factor: 4.965

10.  Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone.

Authors:  L Moro; R S Pozzi Mucelli; C Gazzarrini; C Modricky; F Marotti; B de Bernard
Journal:  Calcif Tissue Int       Date:  1988-02       Impact factor: 4.333

View more
  5 in total

Review 1.  Bone remodeling markers: assessment of fracture risk and fracture risk reduction.

Authors:  Aubrey Blumsohn
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

2.  Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report.

Authors:  Ana Luiza Andrade Aragão; Ivani Novato Silva
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-21

3.  Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration.

Authors:  Mithila Boche; Varsha Pokharkar
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

4.  Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women.

Authors:  Heiner K Berthold; Susanne Unverdorben; Armin Zittermann; Ralf Degenhardt; Bernhard Baumeister; Martin Unverdorben; Wilhelm Krone; Hans Vetter; Ioanna Gouni-Berthold
Journal:  Osteoporos Int       Date:  2004-02-14       Impact factor: 4.507

5.  Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.

Authors:  T Saarto; C Blomqvist; J Risteli; L Risteli; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.